Pacific Biosciences of California PACB Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$128.58M+76.5% | -$546.38M-8.0% | -$506.01M+4.3% | -$528.73M+19.9% | -$660.12M-111% | ||
| $10.06M-22.6% | $12.99M-0.8% | $13.09M-11.7% | $14.83M-5.4% | $15.67M+13.7% | ||
| $36.93M-11.4% | $41.67M-13.4% | $48.11M-13.1% | $55.39M-8.8% | $60.71M-14.5% | ||
| —— | —— | —— | —— | -$751K-266% | ||
| $0-100% | $15M— | —— | —— | —— | ||
| —— | —— | —— | -$176K— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$315K-113% | $2.48M-43.4% | $4.39M+276% | -$2.49M— | —— | ||
| $3.16M+0.1% | $3.16M— | —— | —— | —— | ||
| -$2.8M+67.1% | -$8.51M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$1.19M+29.3% | -$1.69M-1,070% | $174K-35.8% | $271K-13.1% | $312K-50.3% | ||
| —— | —— | —— | —— | -$2.38M-12.8% | ||
| $4.08M-98.9% | $369.45M-1.6% | $375.28M-1.5% | $381.12M-1.5% | $386.95M+1,312% | ||
| $3.57M-10.3% | $3.98M-8.3% | $4.34M-48.8% | $8.47M-26.4% | $11.5M-5.5% | ||
| $3.77M+421% | $723K+122% | -$3.33M+62.6% | -$8.9M+20.2% | -$11.16M+6.4% | ||
| $0+100% | -$18.7M+9.4% | -$20.65M-6.0% | -$19.48M0.0% | -$19.48M-2,192% | ||
| -$111.84M-0.6% | -$111.21M+9.4% | -$122.79M+17.9% | -$149.55M+14.3% | -$174.43M+15.3% | ||
| $4.45M+59.1% | $2.8M-21.3% | $3.56M— | —— | —— | ||
| $207.54M-4.3% | $216.91M-17.9% | $264.29M-15.6% | $313.06M-15.1% | $368.55M-26.1% | ||
| -$65.19M— | $0-100% | $26.8M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $5M— | ||
| $106.07M-8.1% | $115.45M-21.8% | $147.66M-2.7% | $151.82M-25.3% | $203.37M+64.0% | ||
| -$522K— | $0-100% | $3.43M+75.0% | $1.96M0.0% | $1.96M— | ||
| —— | —— | —— | —— | -$47.58M-10.7% | ||
| -$2.87M-137% | $7.67M+135% | -$21.91M+51.5% | -$45.16M— | —— | ||
| —— | $8.26M-16.5% | $9.9M-14.2% | $11.53M-12.4% | $13.17M-11.0% | ||
| $4.08M-98.9% | $369.45M-1.6% | $375.28M-1.5% | $381.12M-1.5% | $386.95M+1,312% | ||
| $0+100% | -$18.7M+9.4% | -$20.65M-6.0% | -$19.48M0.0% | -$19.48M-2,192% | ||
| $10.06M-22.6% | $12.99M-0.8% | $13.09M-11.7% | $14.83M-5.4% | $15.67M+13.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $38.6M-50.0% | $77.2M-33.3% | $115.81M-25.0% | ||
| $3.77M+421% | $723K+122% | -$3.33M+62.6% | -$8.9M+20.2% | -$11.16M+6.4% | ||
| -$2.8M+67.1% | -$8.51M— | —— | —— | —— | ||
| $2.16M-77.9% | $9.77M-8.5% | $10.67M+13.0% | $9.45M-24.3% | $12.48M+159% | ||
| $2.95M-32.3% | $4.37M-30.6% | $6.29M-25.6% | $8.45M-21.1% | $10.72M-17.8% | ||
| $3.57M-10.3% | $3.98M-8.3% | $4.34M-48.8% | $8.47M-26.4% | $11.5M-5.5% | ||
| -$1.19M+29.3% | -$1.69M-1,070% | $174K-35.8% | $271K-13.1% | $312K-50.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $5M— | ||
| $274.88M-19.2% | $340.07M-13.6% | $393.62M-10.1% | $437.8M-19.8% | $545.76M-8.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $12.55M-50.0% | $25.1M-33.3% | $37.65M-25.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$2.38M-12.8% | ||
| $3.77M+421% | $723K+122% | -$3.33M+62.6% | -$8.9M+20.2% | -$11.16M+6.4% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | —— | ||
| -$116.21M-2.0% | -$113.92M+9.8% | -$126.26M+17.1% | -$152.32M+14.5% | -$178.13M+16.1% | ||
| -$116.21M-2.0% | -$113.92M+9.8% | -$126.26M+17.1% | -$152.32M+14.5% | -$178.13M+16.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pacific Biosciences of California generate?
- Pacific Biosciences of California (PACB) generated -$111.8M in operating cash flow over the trailing twelve months.
- What is Pacific Biosciences of California's free cash flow?
- After $4.5M of capital expenditures, Pacific Biosciences of California's free cash flow was -$116.2M over the trailing twelve months, up 34.8% year over year.
- Where does Pacific Biosciences of California's cash flow data come from?
- Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
